Midi Health vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Midi Health
Best for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss productStarting at $128/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | Midi Health | Wisp |
|---|---|---|
| Overall Score | 7.0/10 | 7.0/10 |
| Starting Price | ✓$128/mo | $225/mo |
| Editorial Rating | 3.5 ★ /5 | 3.5 ★ /5 |
| Features | 4 features | ✓6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Midi Health
Pros
- ✓Nationwide availability in all 50 states (verified on the public homepage)
- ✓Accepts commercial insurance — differentiator vs most cash-pay-only GLP-1 telehealth
- ✓Menopause + metabolic health specialty framing — useful for women in the demographic where GLP-1 efficacy and weight regulation overlap most
- ✓Compounded semaglutide pricing starts at $127.90/mo for uninsured patients per the public pricing/insurance page
Cons
- ✗Does NOT accept Medicare, Medicaid, or Medi-Cal — eliminates roughly 40% of the insured US adult population
- ✗GLP-1 prescribing is clinician-discretionary inside a broader menopause care plan, NOT a guaranteed offering at intake — readers signing up purely for GLP-1 access may not get it
- ✗Menopause-focused — not the right fit for men or younger women whose primary need is weight loss
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Both Midi Health and Wisp score equally well overall — the right choice depends on your priorities. Choose Midi Health if you want women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss product, or Wisp if buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested matters most to you.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.